CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 112 enrolled
Drug / intervention
acyclovir sodiumdrug
Likely dose
Acyclovir sodium IV (specific dose determined by randomization to low-dose versus weight-based regimen)AI-extracted
Key inclusion· 6
  • ✓Age ≥18 years
  • ✓Inpatient oncology patient at Wake Forest University Baptist Medical Center
  • ✓Currently receiving or recently received chemotherapy (within 2 weeks)
  • ✓HSV-1 or HSV-2 seropositive (positive immunoglobulin antibody)
Key exclusion· 5
  • ✕Pregnant or nursing
  • ✕Hypersensitivity or allergy to acyclovir sodium
  • ✕High tumor burden with WBC >50,000/mm³ at admission
  • ✕Already receiving 5 mg/kg acyclovir sodium every 8 hours

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00855309
NCT00855309Phase 3Completed
CompareCT.gov

Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient

Wake Forest University Health Sciences·interventional·Posted Mar 4, 2009·Updated Jul 6, 2018

In Brief

A Phase 3 clinical trial evaluating acyclovir sodium for Herpes Simplex. Completed, enrolled 112 participants across 1 site.

Detailed Summary

RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Simplex
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 4, 2009
Enrollment StartNov 1, 2008
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 17.3 years ago

Interventions

acyclovir sodiumdrug

Given IV